Pharmacologic class: Biological response modifier
Therapeutic class: Antineoplastic
Pregnancy risk category C
Enhances cellular toxicity and killer cell activity and promotes generation of oxygen metabolites in phagocytes, resulting in destruction of microorganisms.
Injection: 100 mcg (2 million international units)/0.5-ml vial
Indications and dosages
➣ Chronic granulomatous disease; severe malignant osteoperosis
Adults with body surface area (BSA) above 0.5 m2: 50 mcg/m2 (1 million international units/m2) subcutaneously three times weekly
Adults with BSA of 0.5 m2 or less: 1.5 mcg/kg subcutaneously three times weekly in deltoid or anterior thigh
• Hypersensitivity to drug, its components, or Escherichia coli-derived products
Use cautiously in:
• thyroid disorders, bone marrow depression, hepatic or cardiac disease, seizure disorders, compromised CNS function
• pregnant or breastfeeding patients
• children ages 18 and younger.
• Administer into deltoid muscle by subcutaneous route only.
• Give at bedtime if flulike symptoms occur.
• Provide antiemetics to ease nausea and vomiting, as prescribed.
CNS: dizziness, confusion, paresthesia, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise
CV: chest pain, hypertension, palpitations, arrhythmias
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, pancreatitis
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia
Musculoskeletal: joint pain, back pain, myalgia
Skin: flushing, rash, dry skin, erythema
Other: flulike symptoms, weight loss, edema, hypersensitivity reaction
Drug-drug. Bone marrow depressants: increased bone marrow depression
Zidovudine: increased zidovudine blood level
Drug-diagnostic tests. Hepatic enzymes: increased levels
Neutrophils, platelets: decreased counts
☞ Before and monthly during therapy, assess CBC with white cell differential, glucose and electrolyte levels, and liver and kidney function tests.
• Assess fluid intake and output. Keep patient well hydrated.
• Monitor for GI upset. Provide small, frequent meals or antiemetics to ease severe nausea and vomiting.
☞ Monitor patient for mental status changes and depression.
• Assess for flulike symptoms. If these occur, give drug at bedtime and provide supportive care, such as rest and acetaminophen for headache and fever.
• Teach patient or caregiver how to administer drug subcutaneously, rotate injection sites, and track dosing schedule and injection sites on calendar.
☞ Tell patient to contact prescriber immediately if depression occurs.
• Advise patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception.
• Tell female patient to consult prescriber before breastfeeding.
• Tell patient he'll need regular follow-up examinations and blood tests to monitor drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.